TL;DR
Ten side-by-side life-sciences insurance comparisons. Decision-stage briefings on the structural choices that drive sponsor MSA compliance, balance-sheet protection, and renewal cost. Each comparison answers one specific question and links to the relevant practice page.
Comparison hub
The ten comparisons life-sciences operators ask most. Each is a structured side-by-side: who needs what, when each option is acceptable, and how to negotiate. Use these as the starting point for a coverage architecture decision, then run the MSA Decoder against your contract.
How does insurance differ between patient-specific 503A compounding and FDA-registered 503B outsourcing facilities?
For: Compounding pharmacy operators evaluating the 503B regulatory path.
How do development services change a contract manufacturer's insurance program?
For: Contract manufacturers offering or expanding into formulation/process development.
How do the programs differ between pharmaceutical contract manufacturers and 503B outsourcing facilities?
For: Operators evaluating whether to operate as a CDMO or pursue 503B registration.
Which policy form do sponsor MSAs require, and when is each acceptable?
For: Operators evaluating an existing claims-made program against sponsor MSA requirements.
Which indemnity structure should you push for in a sponsor MSA, and when is each acceptable?
For: CFOs and GCs negotiating sponsor MSA indemnity language.
How should you size the products and completed operations tower?
For: Operators sizing the products tower against the toughest sponsor MSA on file.
How do directors-and-officers liability and errors-and-omissions differ, and when do you need each?
For: Founders, CFOs, and GCs scaling the operating entity.
How do MSA insurance requirements differ between branded innovator and generic pharma sponsors?
For: CDMO and CRO operators evaluating sponsor MSA reads across sponsor types.
How do products liability and professional liability differ in scope and trigger?
For: CDMOs, CROs, medical device manufacturers managing the gap between the two coverages.
When should biotech operators consider a captive insurance structure vs traditional commercial coverage?
For: Biotech operators at revenue scale considering captive insurance economics.
Decided on a structure
Run the MSA Decoder to see if your current contract requires it.
Open the MSA Decoder